Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032

Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032


Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032

Europe Anti-Obesity Drugs Market Outlook

The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of obesity. The global market is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.

Key Takeaways
  • In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. The rising prevalence of obesity is expected to drive market demand.
  • One of the major Europe anti-obesity drugs market trends is the increased investment in obesity drug production to reduce shortages and improve accessibility for weight loss medications. In November 2023, Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs, including Wegovy and Ozempic.
  • Expansion in production facilities is poised to address manufacturing needs and stimulate innovation in the anti-obesity drugs in the region. In November 2023, Eli Lilly and Company invested USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs including Mounjaro and Trulicity.
Europe Anti-Obesity Drugs Market Analysis

The market is witnessing steady growth driven by the increasing prevalence of obesity in the region. Various factors such as unhealthy eating habits, sedentary lifestyles, and certain genetic predispositions, among others, are resulting in the sharp growth of the bariatric population. In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. With the rising obesity prevalence, the Europe anti-obesity drugs market demand is likely to witness a surge owing to the efficacy of these medications in managing weight and reducing associated health risks.

One of the major market trends is the increased investment in anti-obesity drug production by the leading market players to meet the growing demand for weight management medications. In November 2023, the global healthcare company Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs. The funding will amplify the manufacturing capacity for Novo’s popular weight loss drugs, Wegovy and Ozempic, along with other obesity treatments under development. Such substantial investments are expected to reduce shortages and improve accessibility for weight loss medications, thereby propelling the Europe anti-obesity drugs market growth in the forecast period.

In November 2023, a similar investment initiative was taken by Eli Lilly and Company, intended to address the soaring demand for anti-obesity drugs in Europe. The company revealed its plan to invest USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs such as Mounjaro and Trulicity. The expansion of such production facilities in the region is poised to accommodate manufacturing needs and stimulate innovation in the obesity treatment segment, thereby fuelling market share.

Europe Anti-Obesity Drugs Market Segmentation  

Market Breakup by Drugs
  • Semaglutide
  • Phentermine/Topiramate
  • Naltrexone/Bupropion
  • Liraglutide
  • Gelesis 100
  • Orlistat
  • Phentermine
  • Methamphetamine
  • Tirzepatide
Market Breakup by Drug Class
  • Amphetamine
  • GLP-1 Receptor Agonist
  • Lipase Inhibitor
Market Breakup by Mechanism of Action
  • Centrally Acting Drugs
  • Peripherally Acting Drugs
Market Breakup by Route of Administration
  • Oral
  • Subcutaneous
Market Breakup by Prescription Type
  • Prescription Drugs
  • Over The Counter Drugs
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Pharmacies
Market Breakup by Region
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
Europe Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • VIVUS Inc
  • Pfizer, Inc.
  • Novo Nordisk
  • Bayer AG
  • F. Hoffmann-La Roche
  • Glaxosmithkline
  • Arena Pharmaceuticals
  • Eisai Co. Ltd
  • Takeda Pharmaceutical Company
  • Nalpropion Pharmaceuticals Inc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs
  • What is the Europe anti-obesity drugs market forecast outlook for 2024-2032?
The Europe anti-obesity drugs market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.70% during the forecast period of 2024-2032 and is likely to reach a market value of USD 6.3 billion by 2032.
  • What are the major factors aiding the Europe anti-obesity drugs market demand?
The rising prevalence of obesity and heightened awareness about the health risks associated with obesity are fuelling the demand for the market.
  • What are the major Europe anti-obesity drugs market trends?
One of the significant trends in the market is the increased investment in anti-obesity drug production by the leading market players to meet the growing demand for weight management medications. In November 2023, the global healthcare company Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs.
  • What is the market segmentation based on the drugs?
Based on the drugs, the market is segmented into semaglutide, phentermine/topiramate, naltrexone/bupropion, liraglutide, gelesis 100, orlistat, phentermine, methamphetamine, and tirzepatide.
  • What are the various drug classes available in the market?
Drug classes available in the market include amphetamine, GLP-1 receptor agonist, and lipase inhibitors.
  • What is the market breakup by mechanism of action?
By mechanism of action, the market is divided into centrally acting drugs and peripherally acting drugs.
  • What is the market segmentation based on the route of administration?
The market breakup by route of administration includes oral and subcutaneous.
  • What is the market segmentation based on the prescription type?
The market breakup by prescription type includes prescription drugs and over the counter drugs.
  • What are the major distribution channels of anti-obesity drugs?
Distribution channels of the market are hospital pharmacies, drug store & retail pharmacies, and online pharmacies.
  • What is the market segmentation by countries?
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.
  • Who are the key players involved in the Europe anti-obesity drugs market?
The key players in the market are VIVUS Inc., Pfizer, Inc., Novo Nordisk, Bayer AG, F. Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc.

Meta description

The Europe anti-obesity drugs market is poised for growth, driven by the expansion of the global market, which was valued at USD 2.5 billion in 2023 and is projected to grow at a CAGR of 10.70% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Anti-Obesity Drugs Market Overview
3.1 Europe Anti-Obesity Drugs Market Historical Value (2017-2023)
3.2 Europe Anti-Obesity Drugs Market Forecast Value (2024-2032)
4 Europe Anti-Obesity Drugs Market Landscape*
4.1 Europe Anti-Obesity Drugs Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Anti-Obesity Drugs Market: Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Material
4.2.3 Analysis by Type
5 Europe Anti-Obesity Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Anti-Obesity Drugs Market Segmentation (2017-2032)
6.1 Europe Anti-Obesity Drugs Market (2017-2032) by Drugs
6.1.1 Market Overview
6.1.2 Semaglutide
6.1.3 Phentermine/Topiramate
6.1.4 Naltrexone/Bupropion
6.1.5 Liraglutide
6.1.6 Gelesis 100
6.1.7 Orlistat
6.1.8 Phentermine
6.1.9 Methamphetamine
6.1.10 Tirzepatide
6.2 Europe Anti-Obesity Drugs Market (2017-2032) by Drug Class
6.2.1 Market Overview
6.2.2 Amphetamine
6.2.3 GLP-1 receptor agonist
6.2.4 Lipase Inhibitor
6.3 Europe Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
6.3.1 Market Overview
6.3.2 Centrally Acting Drugs
6.3.3 Peripherally Acting Drugs
6.4 Europe Anti-Obesity Drugs Market (2017-2032) by Route of Administration
6.4.1 Market Overview
6.4.2 Oral
6.4.3 Subcutaneous
6.5 Europe Anti-Obesity Drugs Market (2017-2032) by Prescription Type
6.5.1 Market Overview
6.5.2 Prescription Drugs
6.5.3 Over The Counter Drugs
6.6 Europe Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Drug Store & Retail Pharmacies
6.6.4 Online Pharmacies
6.7 Europe Anti-Obesity Drugs Market (2017-2032) by Countries
6.7.1 Market Overview
6.7.2 United Kingdom
6.7.3 Germany
6.7.4 France
6.7.5 Italy
6.7.6 Others
7 United Kingdom Anti-Obesity Drugs Market (2017-2032)
7.1 United Kingdom Anti-Obesity Drugs Market (2017-2032) By Drugs
7.1.1 Market Overview
7.1.2 Semaglutide
7.1.3 Phentermine/Topiramate
7.1.4 Naltrexone/Bupropion
7.1.5 Liraglutide
7.1.6 Gelesis 100
7.1.7 Orlistat
7.1.8 Phentermine
7.1.9 Methamphetamine
7.1.10 Tirzepatide
7.2 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Drug Class
7.2.1 Market Overview
7.2.2 Market Overview
7.2.3 Amphetamine
7.2.4 GLP-1 receptor agonist
7.2.5 Lipase Inhibitor
7.3 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
7.3.1 Market Overview
7.3.2 Centrally Acting Drugs
7.3.3 Peripherally Acting Drugs
7.4 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Route of Administration
7.4.1 Market Overview
7.4.2 Oral
7.4.3 Subcutaneous
7.5 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Prescription Type
7.5.1 Market Overview
7.5.2 Prescription Drugs
7.5.3 Over The Counter Drugs
7.6 United Kingdom Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
7.6.1 Market Overview
7.6.2 Hospital Pharmacies
7.6.3 Drug Store & Retail Pharmacies
7.6.4 Online Pharmacies
8 Germany Anti-Obesity Drugs Market (2017-2032)
8.1 Germany Anti-Obesity Drugs Market (2017-2032) By Drugs
8.1.1 Market Overview
8.1.2 Semaglutide
8.1.3 Phentermine/Topiramate
8.1.4 Naltrexone/Bupropion
8.1.5 Liraglutide
8.1.6 Gelesis 100
8.1.7 Orlistat
8.1.8 Phentermine
8.1.9 Methamphetamine
8.1.10 Tirzepatide
8.2 Germany Anti-Obesity Drugs Market (2017-2032) by Drug Class
8.2.1 Market Overview
8.2.2 Market Overview
8.2.3 Amphetamine
8.2.4 GLP-1 receptor agonist
8.2.5 Lipase Inhibitor
8.3 Germany Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
8.3.1 Market Overview
8.3.2 Centrally Acting Drugs
8.3.3 Peripherally Acting Drugs
8.4 Germany Anti-Obesity Drugs Market (2017-2032) by Route of Administration
8.4.1 Market Overview
8.4.2 Oral
8.4.3 Subcutaneous
8.5 Germany Anti-Obesity Drugs Market (2017-2032) by Prescription Type
8.5.1 Market Overview
8.5.2 Prescription Drugs
8.5.3 Over The Counter Drugs
8.6 Germany Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
8.6.1 Market Overview
8.6.2 Hospital Pharmacies
8.6.3 Drug Store & Retail Pharmacies
8.6.4 Online Pharmacies
9 France Anti-Obesity Drugs Market (2017-2032)
9.1 France Anti-Obesity Drugs Market (2017-2032) By Drugs
9.1.1 Market Overview
9.1.2 Semaglutide
9.1.3 Phentermine/Topiramate
9.1.4 Naltrexone/Bupropion
9.1.5 Liraglutide
9.1.6 Gelesis 100
9.1.7 Orlistat
9.1.8 Phentermine
9.1.9 Methamphetamine
9.1.10 Tirzepatide
9.2 France Anti-Obesity Drugs Market (2017-2032) by Drug Class
9.2.1 Market Overview
9.2.2 Market Overview
9.2.3 Amphetamine
9.2.4 GLP-1 receptor agonist
9.2.5 Lipase Inhibitor
9.3 France Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
9.3.1 Market Overview
9.3.2 Centrally Acting Drugs
9.3.3 Peripherally Acting Drugs
9.4 France Anti-Obesity Drugs Market (2017-2032) by Route of Administration
9.4.1 Market Overview
9.4.2 Oral
9.4.3 Subcutaneous
9.5 France Anti-Obesity Drugs Market (2017-2032) by Prescription Type
9.5.1 Market Overview
9.5.2 Prescription Drugs
9.5.3 Over The Counter Drugs
9.6 France Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
9.6.1 Market Overview
9.6.2 Hospital Pharmacies
9.6.3 Drug Store & Retail Pharmacies
9.6.4 Online Pharmacies
10 Italy Anti-Obesity Drugs Market (2017-2032)
10.1 Italy Anti-Obesity Drugs Market (2017-2032) By Drugs
10.1.1 Market Overview
10.1.2 Semaglutide
10.1.3 Phentermine/Topiramate
10.1.4 Naltrexone/Bupropion
10.1.5 Liraglutide
10.1.6 Gelesis 100
10.1.7 Orlistat
10.1.8 Phentermine
10.1.9 Methamphetamine
10.1.10 Tirzepatide
10.2 Italy Anti-Obesity Drugs Market (2017-2032) by Drug Class
10.2.1 Market Overview
10.2.2 Market Overview
10.2.3 Amphetamine
10.2.4 GLP-1 receptor agonist
10.2.5 Lipase Inhibitor
10.3 Italy Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
10.3.1 Market Overview
10.3.2 Centrally Acting Drugs
10.3.3 Peripherally Acting Drugs
10.4 Italy Anti-Obesity Drugs Market (2017-2032) by Route of Administration
10.4.1 Market Overview
10.4.2 Oral
10.4.3 Subcutaneous
10.5 Italy Anti-Obesity Drugs Market (2017-2032) by Prescription Type
10.5.1 Market Overview
10.5.2 Prescription Drugs
10.5.3 Over The Counter Drugs
10.6 Italy Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
10.6.1 Market Overview
10.6.2 Hospital Pharmacies
10.6.3 Drug Store & Retail Pharmacies
10.6.4 Online Pharmacies
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Funding and Investment Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Supplier Landscape
15.1 Market Share by Top 5 Companies
15.2 VIVUS Inc
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Pfizer, Inc.
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Novo Nordisk
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Bayer AG
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 F Hoffmann-La Roche
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Glaxosmithkline
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Arena Pharmaceuticals
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Eisai Co. Ltd
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Takeda Pharmaceutical Company
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Nalpropion Pharmaceuticals Inc
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Europe Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings